Antipneumocystis activity of 17C91, a prodrug of atovaquone.
The prophylactic efficacy of 17C91, a carbamate prodrug of atovaquone (ATQ), was investigated in a severe combined immunodeficient mouse model of Pneumocystis carinii pneumonia (PCP). At an oral dosage equivalent to 100 mg of ATQ per kg of body weight per day, 17C91 protected 9 of 10 mice from PCP a...
Tallennettuna:
| Julkaisussa: | Antimicrob Agents Chemother |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Microbiology (ASM)
1995
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162917/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8619570/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.10.2217 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|